Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on April 27, 2026. The filing discloses clinical data from the Phase 1/2 ReDiscover trial and announces plans to advance the company's lead candidate, zovegalisib, into Phase 3 development for the treatment of metastatic breast cancer.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and strategic development plans.
Material Changes and Clinical Data
The primary material event is the release of clinical data from the ReDiscover trial as of the April 13, 2026 data cut-off date. Key findings include:
- Study Population: 69 total patients enrolled; 62 patients at or below the potential Phase 3 dose; 34 patients evaluable for response. Patients were heavily pre-treated (median of two prior therapies in the metastatic setting).
- Efficacy: Objective Response Rate (ORR) was 44% (15/34). Nearly all patients (85%) experienced tumor reduction. The ORR approached that of current standard of care doublets in first-line patients (53% to 55%).
- Safety: Only 3% of patients discontinued zovegalisib due to treatment-related adverse events (TRAEs). Grade 3 hyperglycemia was 0% despite 47% of patients being pre-diabetic. The overall grade 3+ TRAE rate was 40%, with neutropenia accounting for the majority of events. No febrile neutropenia was observed.
- Pharmacokinetics: Atirmociclib increased zovegalisib exposure by approximately 2.5-fold. The potential Phase 3 dose is set at 150mg twice daily.
Guidance, Outlook, and Risks
Phase 3 Development Plans: The Company plans to initiate a randomized Phase 3 trial evaluating zovegalisib plus atirmociclib plus an aromatase inhibitor (AI) in first-line (1L) endocrine-sensitive patients with PIK3CA-mutated, HR+/HER2- advanced or metastatic breast cancer. The control arm will consist of a CDK4/6 inhibitor plus AI. Primary and secondary endpoints are median progression-free survival and overall survival, respectively.
Partnership: Pfizer, Inc. has agreed to supply atirmociclib for the experimental arm and palbociclib for the control arm under a clinical trial supply agreement. Relay Therapeutics will sponsor, operationalize, and fund the trial.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the potential for interim data to change, delays in clinical trials, regulatory feedback, and the inability to demonstrate safety and efficacy in future trials. The Company explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the regulatory feedback received regarding the proposed Phase 3 dose (150mg BID) and study design.
- Monitor the timeline for the initiation of the Phase 3 trial and the supply agreement execution with Pfizer.
- Review the full clinical data presentation (Exhibit 99.2) for detailed safety profiles and subgroup analyses.
- Assess the company's cash runway and funding requirements to support the fully operationalized Phase 3 trial.
- Track the maturity of progression-free survival data as the current follow-up (7.4 months) is not yet sufficient for estimation.